OKYO Pharma Ltd

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It targets to cure and prevent the following conditions: dry eye disease, non-infectious anterior uveitis, allergic conjunctivitis, and ocular pain. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.

LONDON and NEW YORK, March 16, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its planned trial evaluating the efficacy and safety of OK-101 in subjects with DED has been posted on the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208). ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website

OKYO Pharma (NASDAQ: OKYO ) stock is heading lower on Tuesday after the company revealed details of a stock offering for its American Depositary Shares (ADSs). OKYO Pharma has revealed plans to sell 3,503,665 ADSs of OKYO stock to certain investors.

Why Is OKYO Pharma (OKYO) Stock Down 10% Today?

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW.

OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management

LONDON, March 13, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) (“OKYO Pharma” or the “Company“), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases (“DED”) and ocular pain, announced the pricing of a reasonable best efforts public offering of 3,503,665 American Depositary Shares (the “ADSs”) at a public offering price of $1.50 per ADS. The gross proceeds to the Company from this offering are expected to be approximately $5.3 million before deducting offering expenses. The offering is expected to close on March 15, 2023, subject to customary closing conditions.

OKYO Pharma Limited Prices $5.3 Million Offering of ADSs

OKYO Pharma (NASDAQ: OKYO ) stock is taking a beating on Wednesday despite recent progress toward a clinical trial. The latest news from OKYO Pharma is that its GMP-packaged OK-101 drug for a Phase 2 clinical trial has cleared customs in the U.S. The company intends to use this drug in its trial to treat dry eye disease (DED).

Why Is OKYO Pharma (OKYO) Stock Down 31% Today?

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO), the ophthalmology-focused bio-pharma company, has announced that its GMP-packaged drug has cleared customs in the United States. OK-101 will be used in the upcoming phase II clinical trial, the first-in-human trial for the treatment of dry eye disease (DED).

OKYO Pharma making final preparations for upcoming clinical trial of dry eye disease drug

LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which was recently shipped from Europe, has cleared customs in the United States.

OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) has appointed Dr Jay Pepose, founder and medical director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine, to its Scientific Advisory Board (SAB). Pepose, a renowned ophthalmologist with expertise in the medical and surgical treatment of ocular surface diseases, will play a pivotal role in guiding OKYO's clinical programme for its dry eye disease (DED) treatment, OK-101.

OKYO Pharma appoints leading US ophthalmology expert to its scientific board

World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to Its Scientific Advisory Board

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) has released its interim results for the six months ended 30 September 2022, a period in which its primary focus was on the development of its Dry Eye Disease (DED) drug, OK-101.

OKYO Pharma eyes progress for OK-101 in 2023, releases interim results

LONDON and NEW YORK, Dec. 30, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announces its interim results for the six months ended 30 September 2022.

OKYO Pharma Limited - Interim Results for the Six Months Ending 30 September 2022

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said its dry eye disease treatment has received its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to initiate a phase 2 study. First-in-human clinical studies of OK-101 are expected to open for enrolment in the first quarter of 2023, the biopharmaceutical company said.

OKYO Pharma receives US FDA license to start Phase 2 study

- OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-

OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease

LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announced today that the Company is participating in the Biotech Showcase in San Francisco, California from January 9-11, 2023 and will be hosting institutional investor and partnering meetings both at the event and online.

OKYO to Participate at Biotech Showcase

LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces, that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a secondary public offering of its American Depositary Shares ("ADSs"), each of which will represent 65 of the Company's ordinary shares of no par value each ("Ordinary Shares") in the United States (the "Offering").

OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC

LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar dry eye disease market, announces that the board of directors of the Company (the "Board" or "Directors"), has appointed PKF Littlejohn LLP (“PKF”) as its new independent auditor with immediate effect.

OKYO Pharma Limited - Change of Auditor

LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, announces that the board of directors of the Company (the "Board" or "Directors"), acting on a recommendation of the Remuneration Committee has awarded Mr Raj Patil, the Company's Chief Scientific Officer, a total of 5,000,000 options at an exercise price of 6.25 pence per share, in recognition of his work in achieving the recent IND filing for OK-101. The options vest immediately and have a life of five years.

OKYO Pharma Limited – PDMR dealing

OKYO Pharma Ltd (LSE:OKYO, NASDAQ:OKYO) said it had filed an investigational new drug application with the US authorities for OK-101, its putative treatment for dry eye disease. It plans to carry out a phase II trial after being allowed to skip the initial safety phase by Food & Drug Administration.

OKYO Pharma applies for the go ahead for phase II trial of its dry eye disease treatment

OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease

Monday, November 14 th @ 8 am ET, registration details below

OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease

New York, New York--(Newsfile Corp. - October 20, 2022) - OKYO Pharma Ltd. (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in the multi-billion-dollar market, will be participating in The ThinkEquity Conference, which will take place on October 26, 2022 at The Mandarin Oriental Hotel in New York. Dr.

OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference

NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Jacob will air on The RedChip Money Report® on Bloomberg TV, this Saturday, September 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

NEW YORK, NY / ACCESSWIRE / September 8 2022 / OKYO Pharma Limited (NASDAQ:OKYO); (LSE:OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Jacob will air on the RedChip Money Report® on Bloomberg TV, this Saturday, September 10, at 7 p.m. Eastern Time (ET).

OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, is pleased to announce that at the Annual General Meeting ("AGM") of the Company held earlier today all resolutions were duly passed.

OKYO Pharma Limited: Result of Annual General Meeting

LONDON & NEW YORK & NORTH AUGUSTA, S.C.--(BUSINESS WIRE)-- #DryEye--OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, plans a Q4 2022 IND filing for OK-101 to treat dry eye disease (DED), with AmbioPharm playing a key role in peptide manufacturing and development. OK-101 is a lipid-peptide analog developed using a novel membrane-anchored peptide (MAP) technology. It con

OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm

News for OKYO Pharma Ltd Stock (OKYO)